Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
暂无分享,去创建一个
A. Yang | Lei Wang | Huayu Zhu | Wen-dong Bai | Xingming Ye | L. Jia | Ting Wang | Ying Chen
[1] Lei Wang,et al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R , 2014, BMC Cancer.
[2] Y Pawitan,et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer , 2013, Oncogene.
[3] R. Bast,et al. Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer , 2012, PloS one.
[4] G. Tsujimoto,et al. Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells , 2012, PloS one.
[5] F. Slack,et al. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.
[6] S. Law,et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor , 2011, Gut.
[7] M. Sliwkowski,et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.
[8] C. Arteaga,et al. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors , 2011, Cancer biology & therapy.
[9] Chang Gong,et al. Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer* , 2011, The Journal of Biological Chemistry.
[10] S. Law,et al. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. , 2010, Cancer research.
[11] H. Park,et al. FoxM1 mediates resistance to herceptin and paclitaxel. , 2010, Cancer research.
[12] Michal Ziv-Ukelson,et al. Gene bi-targeting by viral and human miRNAs , 2010, BMC Bioinformatics.
[13] Douglas Hanahan,et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.
[14] A. Laganà,et al. Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints , 2010, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.
[15] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[16] M. Seto,et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. , 2010, Cancer research.
[17] M. Sliwkowski,et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.
[18] Eran Hornstein,et al. The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas , 2009, PloS one.
[19] C. Hudis,et al. Therapeutic options for metastatic breast cancer , 2009, Expert opinion on pharmacotherapy.
[20] Michael Reiss,et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.
[21] R. Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .
[22] Carlos L Arteaga,et al. Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.
[23] T. Wood,et al. Insulin-like Growth Factor Type-I Receptor Internalization and Recycling Mediate the Sustained Phosphorylation of Akt* , 2007, Journal of Biological Chemistry.
[24] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[25] F. Slack,et al. Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.
[26] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[27] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Angela Greco,et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.
[29] Naoto T. Ueno,et al. P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.
[30] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[31] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[32] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[33] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[34] L. Norton,et al. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis , 1995, Cancer.
[35] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Carlos L. Arteaga,et al. Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.
[37] R. Nishimura,et al. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival , 2008, Breast cancer.
[38] G. Hortobagyi,et al. Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.